Guidelines, RAASi and hyperkalemia: the clinical dilemmas in heart failure
Video navigation menu
- Therapeutic dilemma in managing hyperkalemia while optimizing RAASi therapy 02:03
- Guideline-recommended management of RAASi in the setting of hyperkalemia 03:26
- Consequences of down titration or discontiuation of RAASi therapy due to hyperkalemia 04:51
- Can patients with hyperkalemia receive optimal RAASi therapy? 07:45
This lecture by prof. Andrew Coats was part of the EBAC-accredited symposium "Clinical dilemmas in heart failure: Weighing the balance of RAASi and hyperkalaemia" held during the ESC Heart Failure 2022 congress.
Prof. Andrew J Stewart Coats is Dean of the Royal Australasian College of Physicians, having previously served Dean of Medicine and Deputy Vice-Chancellor of the University of Sydney and head of Cardiology at Imperial College London. He has also served as Joint Academic Vice-President of the University of Warwick, UK, and Monash University, Australia and CEO of the Norwich Research and Innovation Park. He is presently President of the Heart Failure Association of the ESC.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.